Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel Free SUN Stock Alerts

Surgical Innovations Group (SUN) Competitors

Surgical Innovations Group logo
GBX 0.42 0.00 (0.00%)
As of 09/23/2026 05:18 AM Eastern
Compare

SUN vs. AVO, ODX, MHC, CNSL, and BELL

Should you buy Surgical Innovations Group stock or one of its competitors? Surgical Innovations Group's main competitors and comparable companies include Advanced Oncotherapy (AVO), Omega Diagnostics Group (ODX), MyHealthChecked (MHC), Cambridge Nutritional Sciences (CNSL), and Belluscura (BELL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Surgical Innovations Group compare to Advanced Oncotherapy?

Advanced Oncotherapy (LON:AVO) and Surgical Innovations Group (LON:SUN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Surgical Innovations Group has higher revenue and earnings than Advanced Oncotherapy. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A
Surgical Innovations Group£11.60M0.34N/A-£0.10N/A

Advanced Oncotherapy has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, Surgical Innovations Group has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Advanced Oncotherapy has a net margin of 0.00% compared to Surgical Innovations Group's net margin of -4.96%. Surgical Innovations Group's return on equity of -6.04% beat Advanced Oncotherapy's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced OncotherapyN/A -67.34% -11.73%
Surgical Innovations Group -4.96%-6.04%-3.03%

In the previous week, Surgical Innovations Group had 1 more articles in the media than Advanced Oncotherapy. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for Advanced Oncotherapy. Advanced Oncotherapy's average media sentiment score of 0.00 equaled Surgical Innovations Group'saverage media sentiment score.

Company Overall Sentiment
Advanced Oncotherapy Neutral
Surgical Innovations Group Neutral

17.8% of Advanced Oncotherapy shares are owned by institutional investors. Comparatively, 2.8% of Surgical Innovations Group shares are owned by institutional investors. 47.5% of Advanced Oncotherapy shares are owned by company insiders. Comparatively, 22.2% of Surgical Innovations Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Surgical Innovations Group beats Advanced Oncotherapy on 6 of the 10 factors compared between the two stocks.

How does Surgical Innovations Group compare to Omega Diagnostics Group?

Surgical Innovations Group (LON:SUN) and Omega Diagnostics Group (LON:ODX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

2.8% of Surgical Innovations Group shares are owned by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are owned by institutional investors. 22.2% of Surgical Innovations Group shares are owned by insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Surgical Innovations Group has a net margin of -4.96% compared to Omega Diagnostics Group's net margin of -51.15%. Surgical Innovations Group's return on equity of -6.04% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Surgical Innovations Group-4.96% -6.04% -3.03%
Omega Diagnostics Group -51.15%-29.14%-10.53%

In the previous week, Surgical Innovations Group had 1 more articles in the media than Omega Diagnostics Group. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for Omega Diagnostics Group. Surgical Innovations Group's average media sentiment score of 0.00 equaled Omega Diagnostics Group'saverage media sentiment score.

Company Overall Sentiment
Surgical Innovations Group Neutral
Omega Diagnostics Group Neutral

Surgical Innovations Group has higher revenue and earnings than Omega Diagnostics Group. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Omega Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgical Innovations Group£11.60M0.34N/A-£0.10N/A
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

Surgical Innovations Group has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Omega Diagnostics Group has a beta of 3.85, meaning that its stock price is 285% more volatile than the broader market.

Summary

Surgical Innovations Group beats Omega Diagnostics Group on 6 of the 10 factors compared between the two stocks.

How does Surgical Innovations Group compare to MyHealthChecked?

Surgical Innovations Group (LON:SUN) and MyHealthChecked (LON:MHC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Surgical Innovations Group has higher revenue and earnings than MyHealthChecked. Surgical Innovations Group is trading at a lower price-to-earnings ratio than MyHealthChecked, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgical Innovations Group£11.60M0.34N/A-£0.10N/A
MyHealthChecked£3.22M1.48-£1.04M-£3.76N/A

Surgical Innovations Group has a net margin of -4.96% compared to MyHealthChecked's net margin of -49.51%. Surgical Innovations Group's return on equity of -6.04% beat MyHealthChecked's return on equity.

Company Net Margins Return on Equity Return on Assets
Surgical Innovations Group-4.96% -6.04% -3.03%
MyHealthChecked -49.51%-22.78%-8.18%

2.8% of Surgical Innovations Group shares are held by institutional investors. Comparatively, 0.7% of MyHealthChecked shares are held by institutional investors. 22.2% of Surgical Innovations Group shares are held by insiders. Comparatively, 9.3% of MyHealthChecked shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Surgical Innovations Group has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, MyHealthChecked has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

In the previous week, Surgical Innovations Group had 1 more articles in the media than MyHealthChecked. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for MyHealthChecked. Surgical Innovations Group's average media sentiment score of 0.00 equaled MyHealthChecked'saverage media sentiment score.

Company Overall Sentiment
Surgical Innovations Group Neutral
MyHealthChecked Neutral

Summary

Surgical Innovations Group beats MyHealthChecked on 8 of the 11 factors compared between the two stocks.

How does Surgical Innovations Group compare to Cambridge Nutritional Sciences?

Cambridge Nutritional Sciences (LON:CNSL) and Surgical Innovations Group (LON:SUN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Surgical Innovations Group has a net margin of -4.96% compared to Cambridge Nutritional Sciences' net margin of -83.53%. Surgical Innovations Group's return on equity of -6.04% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences-83.53% -69.62% -2.36%
Surgical Innovations Group -4.96%-6.04%-3.03%

In the previous week, Surgical Innovations Group had 1 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for Cambridge Nutritional Sciences. Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled Surgical Innovations Group'saverage media sentiment score.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
Surgical Innovations Group Neutral

Surgical Innovations Group has higher revenue and earnings than Cambridge Nutritional Sciences. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.50-£3.03M£0.602.83
Surgical Innovations Group£11.60M0.34N/A-£0.10N/A

1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. Comparatively, 2.8% of Surgical Innovations Group shares are held by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are held by insiders. Comparatively, 22.2% of Surgical Innovations Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cambridge Nutritional Sciences has a beta of 1.911, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, Surgical Innovations Group has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Summary

Surgical Innovations Group beats Cambridge Nutritional Sciences on 6 of the 11 factors compared between the two stocks.

How does Surgical Innovations Group compare to Belluscura?

Surgical Innovations Group (LON:SUN) and Belluscura (LON:BELL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Surgical Innovations Group has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Belluscura has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

2.8% of Surgical Innovations Group shares are held by institutional investors. Comparatively, 0.2% of Belluscura shares are held by institutional investors. 22.2% of Surgical Innovations Group shares are held by company insiders. Comparatively, 7.1% of Belluscura shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Surgical Innovations Group has higher revenue and earnings than Belluscura. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgical Innovations Group£11.60M0.34N/A-£0.10N/A
Belluscura£1.80M1.67-£29.55M-£13.10N/A

Surgical Innovations Group has a net margin of -4.96% compared to Belluscura's net margin of -2,243.45%. Surgical Innovations Group's return on equity of -6.04% beat Belluscura's return on equity.

Company Net Margins Return on Equity Return on Assets
Surgical Innovations Group-4.96% -6.04% -3.03%
Belluscura -2,243.45%-97.35%-43.53%

In the previous week, Surgical Innovations Group had 1 more articles in the media than Belluscura. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for Belluscura. Surgical Innovations Group's average media sentiment score of 0.00 equaled Belluscura'saverage media sentiment score.

Company Overall Sentiment
Surgical Innovations Group Neutral
Belluscura Neutral

Summary

Surgical Innovations Group beats Belluscura on 8 of the 11 factors compared between the two stocks.

Get Surgical Innovations Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SUN vs. The Competition

Export
MetricSurgical Innovations GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£3.96M£5.63B£7.33B£2.88B
Dividend Yield2.63%1.79%2.52%6.22%
P/E Ratio-4.2525.36274.40366.48
Price / Sales0.3471.23639.6690,069.93
Price / Cash5.0333.0277.8027.89
Price / Book0.435.7410.526.39
Net IncomeN/A£151.55M£3.49B£5.89B
7 Day Performance5.99%-0.36%-1.08%-0.04%
1 Month Performance5.99%-3.98%-3.39%6.15%
1 Year Performance-40.56%5.74%15.08%19.05%

Surgical Innovations Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUN
Surgical Innovations Group
N/AGBX 0.43
flat		N/A-36.3%£3.96M£11.60MN/A80
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/AN/A3,900
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91
MHC
MyHealthChecked
N/AGBX 9.15
+1.7%		N/A-11.5%£4.76M£3.22MN/A16
CNSL
Cambridge Nutritional Sciences
N/AGBX 1.50
-3.2%		N/A-52.4%£3.57M£8.06M2.503,200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SUN) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel